Prevention Trials

 

• STUDY10077
  
  NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
  
  Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
  
  Study Information

  ---

  
  

• STUDY18956
  
  Hybrid Type 1 Effectiveness Implementation Trial of a Proactive Smoking Cessation Electronic Visit for Scalable Delivery via Primary Care
  
  We will conduct a two-arm clinic-randomized clinical trial (N=672) to examine the effectiveness of a smoking cessation electronic visit (e-visit) vs. treatment as usual (TAU) for smoking cessation across 21 MUSC primary care practices. Main outcomes include: 1) evidence-based smoking cessation treatment utilization (medication, psychosocial cessation counseling), 2) reduction in cigarettes per day, and 3) biochemically verified 7-day PPA at six-month follow-up. We hypothesize that smokers randomized to the e-visit condition will have significantly better cessation outcomes relative to TAU. Secondary outcomes will focus on implementation of the e-visit at the patient, provider, and organizational levels.
  
  Study Information

  ---

  
  

• STUDY19843
  
  Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
  
  This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
  
  Study Information

  ---

  
  

• STUDY21506
  
  Addressing Rural Cancer Disparities via Proactive Smoking Cessation Treatment within Primary Care: A Hybrid Type 1 Effectiveness Implementation Trial of a Scalable Smoking Cessation Electronic Visit
  
  We will conduct a Hybrid Type I effectiveness-implementation trial to comprehensively assess effectiveness of a proactive electronic visit (e-visit) for smoking cessation relative to treatment as usual (TAU) while simultaneously evaluating implementation when delivered across rural primary care settings. In Aim 1, we will conduct a stepped-wedge, cluster-randomized clinical trial (N=288) to examine the effectiveness of the smoking cessation e-visit vs. TAU for smoking cessation across seven rural (Rural-Urban Commuting Area codes 4-10) primary care practices in South Carolina. In Aim 2, we will evaluate e-visit implementation outcomes across rural South Carolina primary care settings at patient, provider, and organizational levels. Main outcomes include: 1) biochemically verified 7-day PPA (point prevalence of abstinence) at six-month follow-up, 2) reduction in cigarettes per day, and 3) evidence-based smoking cessation treatment utilization (medication, psychosocial cessation counseling). We hypothesize that rural smokers randomized to the e-visit condition will have significantly better cessation outcomes relative to TAU.
  
  Study Information

  ---

  
  

• STUDY21923
  
  Impact of Cigarette and E Cigarette Menthol Regulation on Current Smokers of Menthol Cigarettes.
  
  Assess the impact of simulated cigarette and e-cigarette menthol regulations on tobacco use patterns among current menthol smokers. Primary outcomes are a) changes in cigarettes per day (CPD) through Week 6, and secondary outcomes include b) e-cigarette use, and c) ability to remain abstinent. Hypothesis: Assignment to non-menthol cigarettes and assignment to menthol e-liquid will a) reduce cigarettes per day, b) increase e-cigarette use, and c) increase the ability to remain abstinent. We hypothesize an interaction such that effects on tobacco use patterns will be greatest for individuals who receive both non-menthol cigarettes and menthol e-liquid.
  
  Study Information

  ---